Table 1 Clinico-pathological variables for the patient cohort (n=464)
From: Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients
Clinico-pathologic variables | n (%) |
|---|---|
Age (years) | |
≤30 | 77 (16.6) |
31 - 40 | 387 (83.4 |
Median (in years) | 36.0 |
Range(IQR)^ | 32.0 – 39.0 |
Family history of breast cancer | |
Yes | 55 (11.9) |
No | 409 (88.1) |
Family history of any cancer | |
Yes | 91 (19.6) |
No | 373 (80.4) |
Personal history of other cancer | |
Yes | 5 (1.1) |
No | 459 (98.9) |
Bilateral breast cancer | |
Yes | 4 (0.9) |
No | 460 (99.1) |
Histological type | |
Infiltrating Ductal carcinoma | 421 (90.7) |
Infiltrating Lobular carcinoma | 19 (4.1) |
Mucinous carcinoma | 10 (2.2) |
Others | 14 (3.0) |
Tumor size | |
≤2 cm | 137 (29.5) |
>2 cm | 311 (67.1) |
Unknown | 16 (3.4) |
Lymph node status | |
Negative | 164 (35.4) |
Positive | 284 (61.2) |
Unknown | 16 (3.4) |
Distant metastasis | |
Absent | 411 (88.6) |
Present | 37 (8.0) |
Unknown | 16 (3.4) |
Histologic Stage | |
I | 71 (15.4) |
II | 170 (36.6) |
III | 170 (36.6) |
IV | 37 (8.0) |
Unknown | 16 (3.4) |
Histologic Grade | |
Well differentiated | 29 (6.3) |
Moderately differentiated | 190 (40.9) |
Poorly differentiated | 218 (47.0) |
Unknown | 27 (5.8) |
Estrogen Receptor | |
Positive | 268 (57.7) |
Negative | 196 (42.3) |
Progesterone Receptor | |
Positive | 238 (51.3) |
Negative | 226 (48.7) |
Her-2 neu | |
Positive | 176 (37.9) |
Negative | 288 (62.1) |
Molecular subtype | |
Luminal | 303 (65.3) |
Her-2 positive | 73 (15.7) |
Triple negative | 88 (19.0) |
BRCA1mutation | |
Present | 41 (8.8) |
Absent | 423 (91.2) |
BRCA2mutation | |
Present | 16 (3.4) |
Absent | 448 (96.6) |
Survival Duration (in months) | |
Median | 55.1 |
Range(IQR)^ | 27.0 – 79.0 |